![]() Principal Investigator, Genentech ARCHWAY Study – Phase III, multi-center, randomized, study of efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with AMD.Principal Investigator, Genentech PAVILLION Study – Phase III, multi-center, randomized, study of efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with NPDR.Principal Investigator, Genentech PAGODA Study- Phase III, multi-center, randomized, study of efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with DME.Principal Investigator, Aldeyra GUARD Trial – Phase III, multi-center, randomized controlled prospective trial of repeated intravitreal injections of ADX-2191 versus standard of care for prevention of PVR after retinal detachment repair.Ocular Surgery News Retina 150 Innovators in Medical and Surgical Retina.Listing in Guide to America’s Top Ophthalmologists.Board of Directors, Illinois Society for the Prevention of Blindness.Co-founding Editor, Annual ASRS Preferences and Trends (PAT) Survey.Executive Committee, Foundation of the ASRS.President, American Society of Retina Specialists (ASRS).Pollack, his wife Susan, and their three children share an enthusiasm for fishing, skiing, and travel. He has served as chairman, principle investigator, or co-investigator in over 20 major national research studies, and is an advisor to pharma, biotech and device companies seeking to develop more effective retina therapies. Pollack’s research interests include retinal cell therapy, retinitis pigmentosa, MacTel, macular degeneration, diabetic retinopathy, retinal vein occlusion, and epiretinal membranes. Pollack became a Charter Inductee into the Retina Hall of Fame, in recognition of exceptional lifetime achievements and contributions to the field of retina.ĭr. He has been listed in “Best Doctors in America”, “Guide to America’s Top Ophthalmologists”, and “IL Top Doctors” for many years. Pollack is recipient of the ASRS Senior Honor Award, the AAO Achievement Award, and has been identified by Ocular Surgery News as one of “OSN Retina 150,” a select group of retina specialists identified by the publication’s editors and publisher as leading innovators in the field of medical and surgical retina. Pollack serves on the Board of Directors of multiple non-profit and commercial medical entities, is co-founding Editor of the widely referenced annual ASRS Preferences and Trends Survey and is co-founder of ‘The Winning Pitch Challenge’, a medical competition that accelerates innovation in ophthalmology.ĭr. He is Past-President of both the American Society of Retina Specialists (ASRS), the largest organization of retina specialists in the world, and the Foundation of the ASRS, which supports patients and the retina community through education, awareness, and fundraising. Pollack has held a number of national leadership positions and received many honors. ![]() He completed his ophthalmology residency at Washington University and his retina fellowship at the Medical College of Wisconsin, in Milwaukee.ĭr. He received his undergraduate degree at Washington University in St. Pollack’s passion for ophthalmology was inspired by his father, who was also an ophthalmologist. He sees patients in our Joliet and Hinsdale locations.ĭr. A recognized leader and innovator in the field of retina, he has delivered over 200 scientific presentations across the globe and has published over 60 scientific papers and book chapters. Pollack has been with Illinois Retina Associates and Rush University Medical Center since 1997. Retinal Detachment Treatment in Illinoisĭr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |